Client news | MedImpact

: Client news; MedImpact investigates the impact of oral semaglutide and diabetes market trends.; With the potential to change the landscape of diabetes treatment, oral semaglutide ushers in the next generation of diabetes care with its anticipated FDA approval in September.; READ MORE

: Client news; Can you put a price on life?; FDA approves world’s most expensive drug with broad indication to treat rare childhood neuromuscular disease.; READ MORE

: Client news; FDA approves first and only treatment for common mutation in advanced breast cancer.; The FDA approved a new drug that is a potential game changer for advanced breast cancer patients. Piqray (alpelisib) gained approval on May 24 for treatment of postmenopausal women and men with one of the most commonly mutated genes in advanced or metastatic breast cancer.; READ MORE

: Client news; Dispelling the myth: generics are not always low cost.; When we hear the terms “generic” or “off-brand,” we typically think that the product would be a significantly cheaper alternative than the name brand. Well, when it comes to generic drugs, that’s not always in the case. Here are five facts plan sponsors should know:; READ MORE

: Client news; National prescription drug take back day helps fight drug abuse.; +5,400 tons. That’s how much the DEA has collected of expired, unwanted or unused prescription medications over the past nine years through the National Prescription Drug Take Back Day program.; READ MORE

: Client news; Paying for cures.; MedImpact sponsors MIT initiative to help make high-cost curative therapies more accessible; READ MORE

: Client news; Combating the opioid crisis together.; MedImpact helps reduce opioid utilization in one of America's most affected states; READ MORE

: Client news; MedImpact activates natural disaster response in wake of Hurricane Michael.; As Hurricane Michael — the strongest hurricane in history to hit the Florida Panhandle — continues to surge through the Southeast with damaging winds and flood-causing rains, MedImpact is committed to providing natural disaster support to our clients and members.; READ MORE

: Client news; FDA approves new preventive treatment for rare hereditary disease.; The U.S. Food and Drug Administration (FDA) recently approved Takhzyro (lanadelumab-flyo) as the first preventive monoclonal antibody to treat hereditary angioedema (HAE) to help prevent attacks in patients 12 years and older. HAE is a rare and potentially life-threatening genetic disease that can cause unpredictable, debilitating episodes of painful swelling in the limbs, abdomen and airway.; READ MORE

Resources.